Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 18

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
— 183 — 183 Dividends declared— — — — (2,913)— — (2,913)Purchases of treasury stock(5)— (963)— — — — (963)Stock-based compensation plans and other6 — 27 475 — — — 502 Change in noncontrolling interest— — — — — — 3 3 Balance at March 31, 20251,766 $18 $(9,137)$21,808 $(9,527)$(1,742)$42 $1,462 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 4

AbbVie Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (unaudited) 

Three months endedMarch 31,(in millions) (brackets denote cash outflows)20252024Cash flows from operating activitiesNet earnings$1,289 $1,372 Adjustments to reconcile net earnings to net cash from operating activities:Depreciation181 183 Amortization of intangible assets1,858 1,891 Deferred income taxes(28)(389)Change in fair value of contingent consideration liabilities1,518 660 Payments of contingent consideration liabilities(549)(391)Stock-based compensation410 348 Acquired IPR&D and milestones248 164 Non-cash litigation reserve adjustments, net of cash payments(729)(12)Other, net17 (33)Changes in operating assets and liabilities, net of acquisitions:Accounts receivable(1,479)(702)Inventories(155)(75)Prepaid expenses and other assets(628)284 Accounts payable and other liabilities(696)362 Income tax assets and liabilities, net378 378 Cash flows from operating activities1,635 4,040 Cash flows from investing activitiesAcquisitions of businesses, net of cash acquired(204)(9,199)Other acquisitions and investments(334)(190)Acquisitions of property and equipment(235)(193)Purchases of investment securities(10)(6)Sales and maturities of investment securities32 6 Other, net16 (6)Cash flows from investing activities(735)(9,588)Cash flows from financing activitiesNet change in commercial paper borrowings